Literature DB >> 23369962

"Special exemptions": should they be put on trial?

H Bobby Gaspar, Sue Swift, Adrian J Thrasher.   

Abstract

Mesh：

Year:  2013        PMID： 23369962      PMCID： PMC3594031          DOI： 10.1038/mt.2013.1

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  9 in total

1.  Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.

Authors:  Ganesh Suntharalingam; Meghan R Perry; Stephen Ward; Stephen J Brett; Andrew Castello-Cortes; Michael D Brunner; Nicki Panoskaltsis
Journal:  N Engl J Med       Date:  2006-08-14       Impact factor: 91.245

2.  Compassionate and innovative treatments in children: a proposal for an ethical framework.

Authors:  Joe Brierley; Vic Larcher
Journal:  Arch Dis Child       Date:  2009-05-19       Impact factor: 3.791

3.  Treatment of chemotherapy-refractory cancer in the advanced therapy access program.

Authors:  Akseli Hemminki
Journal:  Mol Ther       Date:  2012-09       Impact factor: 11.454

4.  Differing approaches to experimental therapeutics: are we a world apart?

Authors:  Timothy P Cripe
Journal:  Mol Ther       Date:  2012-09       Impact factor: 11.454

5.  Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer.

Authors:  Otto Hemminki; Iulia Diaconu; Vincenzo Cerullo; Saila K Pesonen; Anna Kanerva; Timo Joensuu; Kalevi Kairemo; Leena Laasonen; Kaarina Partanen; Lotta Kangasniemi; Andre Lieber; Sari Pesonen; Akseli Hemminki
Journal:  Mol Ther       Date:  2012-08-07       Impact factor: 11.454

6.  Granulocyte colony-stimulating factor recruitment of CD34+ progenitors to peripheral blood: impaired mobilization in chronic granulomatous disease and adenosine deaminase--deficient severe combined immunodeficiency disease patients.

Authors:  S Sekhsaria; T A Fleisher; S Vowells; M Brown; J Miller; I Gordon; R M Blaese; C E Dunbar; S Leitman; H L Malech
Journal:  Blood       Date:  1996-08-01       Impact factor: 22.113

7.  Efficacy of gene therapy for X-linked severe combined immunodeficiency.

Authors:  Salima Hacein-Bey-Abina; Julia Hauer; Annick Lim; Capucine Picard; Gary P Wang; Charles C Berry; Chantal Martinache; Frédéric Rieux-Laucat; Sylvain Latour; Bernd H Belohradsky; Lily Leiva; Ricardo Sorensen; Marianne Debré; Jean Laurent Casanova; Stephane Blanche; Anne Durandy; Frederic D Bushman; Alain Fischer; Marina Cavazzana-Calvo
Journal:  N Engl J Med       Date:  2010-07-22       Impact factor: 91.245

8.  Gene therapy for immunodeficiency due to adenosine deaminase deficiency.

Authors:  Alessandro Aiuti; Federica Cattaneo; Stefania Galimberti; Ulrike Benninghoff; Barbara Cassani; Luciano Callegaro; Samantha Scaramuzza; Grazia Andolfi; Massimiliano Mirolo; Immacolata Brigida; Antonella Tabucchi; Filippo Carlucci; Martha Eibl; Memet Aker; Shimon Slavin; Hamoud Al-Mousa; Abdulaziz Al Ghonaium; Alina Ferster; Andrea Duppenthaler; Luigi Notarangelo; Uwe Wintergerst; Rebecca H Buckley; Marco Bregni; Sarah Marktel; Maria Grazia Valsecchi; Paolo Rossi; Fabio Ciceri; Roberto Miniero; Claudio Bordignon; Maria-Grazia Roncarolo
Journal:  N Engl J Med       Date:  2009-01-29       Impact factor: 91.245

9.  Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency.

Authors:  H Bobby Gaspar; Samantha Cooray; Kimberly C Gilmour; Kathryn L Parsley; Stuart Adams; Steven J Howe; Abdulaziz Al Ghonaium; Jinhua Bayford; Lucinda Brown; E Graham Davies; Christine Kinnon; Adrian J Thrasher
Journal:  Sci Transl Med       Date:  2011-08-24       Impact factor: 17.956
  9 in total
  7 in total

1.  Burn patient care lost in good manufacturing practices?

Authors:  G Dimitropoulos; P Jafari; A de Buys Roessingh; N Hirt-Burri; W Raffoul; L A Applegate
Journal:  Ann Burns Fire Disasters       Date:  2016-06-30

2.  A single epidermal stem cell strategy for safe ex vivo gene therapy.

Authors:  Stéphanie Droz-Georget Lathion; Ariane Rochat; Graham Knott; Alessandra Recchia; Danielle Martinet; Sara Benmohammed; Nicolas Grasset; Andrea Zaffalon; Nathalie Besuchet Schmutz; Emmanuelle Savioz-Dayer; Jacques Samuel Beckmann; Jacques Rougemont; Fulvio Mavilio; Yann Barrandon
Journal:  EMBO Mol Med       Date:  2015-04       Impact factor: 12.137

3.  Retrospective Evaluation of Progenitor Biological Bandage Use: A Complementary and Safe Therapeutic Management Option for Prevention of Hypertrophic Scarring in Pediatric Burn Care.

Authors:  Karim Al-Dourobi; Alexis Laurent; Lina Deghayli; Marjorie Flahaut; Philippe Abdel-Sayed; Corinne Scaletta; Murielle Michetti; Laurent Waselle; Jeanne-Pascale Simon; Oumama El Ezzi; Wassim Raffoul; Lee Ann Applegate; Nathalie Hirt-Burri; Anthony S de Buys Roessingh
Journal:  Pharmaceuticals (Basel)       Date:  2021-02-28

Review 4.  Gene therapy on the move.

Authors:  Kerstin B Kaufmann; Hildegard Büning; Anne Galy; Axel Schambach; Manuel Grez
Journal:  EMBO Mol Med       Date:  2013-09-17       Impact factor: 12.137

Review 5.  The development of T cells from stem cells in mice and humans.

Authors:  Farbod Famili; Anna-Sophia Wiekmeijer; Frank Jt Staal
Journal:  Future Sci OA       Date:  2017-03-16

6.  Holistic Approach of Swiss Fetal Progenitor Cell Banking: Optimizing Safe and Sustainable Substrates for Regenerative Medicine and Biotechnology.

Authors:  Alexis Laurent; Nathalie Hirt-Burri; Corinne Scaletta; Murielle Michetti; Anthony S de Buys Roessingh; Wassim Raffoul; Lee Ann Applegate
Journal:  Front Bioeng Biotechnol       Date:  2020-10-23

7.  Burn Center Organization and Cellular Therapy Integration: Managing Risks and Costs.

Authors:  Michèle Chemali; Alexis Laurent; Corinne Scaletta; Laurent Waselle; Jeanne-Pascale Simon; Murielle Michetti; Jean-François Brunet; Marjorie Flahaut; Nathalie Hirt-Burri; Wassim Raffoul; Lee Ann Applegate; Anthony S de Buys Roessingh; Philippe Abdel-Sayed
Journal:  J Burn Care Res       Date:  2021-09-30       Impact factor: 1.845
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.